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Background: The rate of infections due to extended-spectrum β-lactamase (ESBL)-producing 
Escherichia coli is growing worldwide. These infections are suspected to be related to increased 
mortality. We aimed to estimate the difference in mortality due to bloodstream infections 
(BSIs) with ESBL-positive and ESBL-negative E. coli isolates and to determine the molecular 
epidemiology of our ESBL-positive isolates.
Materials and methods: We performed a cohort study on consecutive patients with E. coli 
BSI between 2008 and 2010 at the Charité University Hospital. Collected data were ESBL 
 production, basic demographic parameters, and underlying diseases by the Charlson comorbidity 
index (CCI). The presence of ESBL genes was analyzed by polymerase chain reaction (PCR) 
and sequencing. Phylogenetic groups of ESBL-positive E. coli were determined by PCR. Risk 
factors for mortality were analyzed by multivariable regression analysis.
Results: We identified 115 patients with BSI due to E. coli with ESBL phenotype and 983 due 
to ESBL-negative E. coli. Fifty-eight percent (n=67) of the ESBL-positive BSIs were hospital-
acquired. Among the 99 isolates that were available for PCR screening and sequencing, we 
found mainly 87 CTX-M producers, with CTX-M-15 (n=55) and CTX-M-1 (n=21) as the most 
common types. Parameters significantly associated with mortality were age, CCI, and length of 
stay before and after onset of BSI.
Conclusion: The most common ESBL genotypes in clinical isolates from E. coli BSIs were 
CTX-M-15 (58%) and CTX-M-1 (22%). ESBL production in clinical E. coli BSI isolates was 
not related to increased mortality. However, the common occurrence of hospital-acquired BSI 
due to ESBL-positive E. coli indicates future challenges for hospitals.
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Background
Infections with extended-spectrum β-lactamase (ESBL)-producing Enterobacteri-
aceae are increasing worldwide.1 In particular, bloodstream infections (BSIs) due to 
ESBL-producing Enterobacteriaceae have been reported to be related to increased 
mortality in the past 10 years.2–4 However, recent studies showed no significant 
 difference in mortality comparing ESBL-positive and ESBL-negative cases of BSI 
due to Enterobacteriaceae.5,6 There is still a lack of current studies with large numbers 
of patients and adequate control cohorts consisting of infections with susceptible 
Enterobacteriaceae. Therefore, we present the results of a large study with more 
than 100 ESBL-positive patients and respective control patients with ESBL-negative 
Escherichia coli BSI.






Setting, study design, and definitions
The study was carried out at the Charité University Hospital 
in Berlin, a 3,213-bed tertiary care center. The study was 
performed in conformity with the ethical guidelines of the 
Declaration of Helsinki. It is based on secondary data, and 
ethical approval was not required.
We conducted a cohort study of all consecutive patients 
with BSI caused by E. coli between January 1, 2008 and 
December 31, 2010. Patients were retrospectively identi-
fied in the Charité microbiology database as patients with 
blood cultures positive for E. coli. For all patients enrolled 
in this study, the following demographic characteristics were 
collected from their electronic files: age, sex, in-hospital 
death, day of BSI onset, and underlying comorbidities by 
the Charlson comorbidity index (CCI) on the basis of the 
patients’ International Classification of Diseases (ICD)-10-
coded diagnoses.7 If a patient had more than one episode of 
E. coli BSI within the analyzed period, the first episode was 
analyzed. Each patient was included in the analysis only once. 
Onset of BSI was defined as the date of the first blood culture 
positive for E. coli. BSI was considered hospital-acquired 
when the onset occurred at least 48 hours after admission.
Microbiological methods, resistance-gene 
screening, and bacterial typing
The VITEK 2 automated system was used for the identi-
fication of E. coli species and antimicrobial susceptibil-
ity testing. The results were interpreted according to the 
Clinical and Laboratory Standards Institute standards.8 
Confirmation of ESBL production was performed by a 
minimum inhibitory concentration dilution test on a multi-
well microtiter plate. Three third-generation cephalosporins 
(cefoxitin, ceftazidime, cefpodoxime) were tested alone 
and in combination with ESBL inhibitor clavulanic acid 
(standard operating procedure according to the German 
Accreditation Council, registration DGA-ML-6243.03). 
All E. coli isolates with ESBL phenotype were screened for 







) by polymerase chain reaction (PCR) and 
subsequent sequencing.9 If none of these ESBL genes 
could be identified, additional PCR tests for the presence 














) were performed. Furthermore, 
basic bacterial typing of all ESBL-positive E. coli isolates 
was performed by a  PCR-based method for determination 
of the four major E. coli phylogenetic groups.11
statistical methods
Parameters in the descriptive analysis of patients with ESBL-
positive and ESBL-negative E. coli BSIs were tested using 
the Wilcoxon rank-sum test for continuous variables and 
Fisher’s exact test for categorical variables. A multivariable 
analysis was performed to estimate the effects of multiple 
factors associated with mortality using a stepwise forward 
regression. Included variables were ESBL production, age, 
sex, CCI, hospital acquisition, and length of stay before 
and after BSI onset. Variables with P-values,0.05 were 
included, and variables with P$0.05 were excluded. Odds 
ratios and their 95% confidence intervals were calculated. All 
tests of significance were two-tailed, with a P-value,0.05 
considered to be significant. Data were analyzed using PASW 
Statistics 18 (IBM, Armonk, NY, USA).
Results
We identified 1,098 consecutive patients with E. coli BSI. 
One hundred and fifteen patients (10.5%) with ESBL-
positive due to E. coli, and 983 patients with BSI due to 
ESBL-negative E. coli (89.5%). The baseline characteristics 
of patients with ESBL-positive and ESBL-negative E. coli 
BSI are shown in Table 1. Overall and regardless of ESBL 
production, 449 (40%) E. coli BSIs were hospital-acquired 
and associated with an in-house mortality of 24% (n=107), 
compared to 16% (n=104, P=0.001) among community-
acquired cases. Fifty-eight percent (n=67) of the ESBL-
positive BSIs and 38% (n=382) of ESBL-negative E. coli 
BSIs (P,0.001) were hospital-acquired. 
The blood culture specimens of 99 (86%) BSI patients 
were available for molecular analysis. ESBL genes were 
identified in 95 E. coli isolates. One isolate was positive for 
AmpC β-lactamase CMY-2, and three isolates were only posi-
tive for β-lactamase type TEM-1 (n=2) and TEM-181 (n=1), 
respectively. All four of these patients were removed from the 
analysis, leaving 95 analyzed patients. Among the remaining 
95 ESBL-producing isolates, CTX-M enzymes (n=87, 92%) 
were predominant, with CTX-M-15 (n=55, 58%), CTX-M-1 
(n=21, 22%), and CTX-M-14 (n=4, 4%) the most common 
ESBL-types (Figure 1A). Furthermore, 43 (45%) of all 
ESBL-producing E. coli additionally harbored TEM-type 
β-lactamases. Among the 54 hospital-acquired ESBL-posi-
tive E. coli isolates that were available for molecular analysis, 
the most common genotypes were CTX-M-15 (n=33, 61%), 
CTX-M-1 (n=10, 19%) and CTX-M-14 (n=3, 6%).
Bacterial typing (Figure 1B) revealed that the 95 ESBL-
producing E. coli isolates belonged to phylogenetic groups B2 
(n=31, 33%), D (n=28, 29%), A (n=26, 27%), and B1 (n=10, 
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Table 1 Baseline characteristics of 1,098 patients with Escherichia 








hospital-acquired BsI* 67 (58%) 382 (39%) ,0.001
age, years 59 (44–71) 67 (54–75) ,0.001
Male* 74 (64%) 521 (53%) 0.018
In-house mortality* 30 (26%) 181 (18%) 0.076
length of hospital  
stay, total days
27 (12–53) 15 (8–32) ,0.001
length of stay before 
BsI onset, days
7 (0–20) 1 (0–10) ,0.001
charlson comorbidity 
index
5 (3–8) 5 (3–8) 0.227
Myocardial infarct* 5 (4%) 28 (3%) 0.381
congestive heart  
failure*
19 (17%) 148 (15%) 0.681
Peripheral vascular  
disease*
19 (17%) 83 (8%) 0.007
cerebrovascular  
disease*
8 (7%) 56 (6%) 0.673
Dementia* 2 (2%) 21 (2%) 1.000
chronic lung disease* 11 (10%) 109 (11%) 0.643
Rheumatic disease* 0 32 (3%) 0.050
Peptic ulcer* 6 (6%) 36 (4%) 0.436
Mild liver disease* 12 (10%) 121 (12%) 0.652
Diabetes without  
complication*
14 (12%) 192 (20%) 0.058
Diabetes with  
complication*
8 (7%) 62 (6%) 0.839
Renal disease* 55 (48%) 425 (43%) 0.372
Malign tumor* 25 (22%) 237 (24%) 0.644
liver disease* 9 (8%) 70 (7%) 0.848
Metastasis* 14 (12%) 139 (14%) 0.577
hIV* 2 (2%) 9 (1%) 0.617
hemiplegia* 5 (4%) 37 (4%) 0.795
leukemia* 15 (13%) 85 (9%) 0.124
lymphoma* 5 (4%) 66 (7%) 0.424
Notes: *categorical variables were tested using Fisher’s exact test, and are 
presented as number (percentage). continuous variables were tested using the 
Wilcoxon rank-sum test, and are presented as medians (interquartile range).
Abbreviations: BsI, bloodstream infection; esBl, extended-spectrum β-lactamase; 
HIV, human immunodeficiency virus.
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10%). The distribution of the phylogenetic groups among 
the 54 hospital-acquired E. coli isolates was nearly identi-
cal. However, considering only the isolates with CTX-M-15 
(n=55) and CTX-M-1 (n=21), phylogenetic group B2 was 
mainly associated with CTX-M-15 (n=24, 44%) in contrast 
to isolates of phylogenetic group A producing mainly CTX-
M-1 (n=10, 48%) (Figure 1C and D).
The results of the regression analysis are shown in 
Table 2. Age, Charlson comorbidity index, and length 
of stay before and after onset of BSI were significantly 
associated with hospital mortality. ESBL production 
was not a  signif icant risk factor in the multivariable 
analysis.
Discussion
In the present single-center cohort study of patients with E. 
coli BSI, we analyzed 115 patients with ESBL-positive and 
983 patients with ESBL-negative E. coli. BSI due to ESBL-
positive E. coli was significantly more often hospital-acquired 
than ESBL-negative E. coli BSI. However, in this study, 
ESBL production was not associated with increased mortality 
risk. In our study, ESBL E. coli BSI was related to an in-
house mortality of 26%. This result is comparable to several 
recent studies that reported ESBL BSI mortality (30-day 
or in-hospital) between 20% and 25%.6,12–14  Nevertheless, 
few published studies have assessed the mortality of ESBL 
or third-generation cephalosporin-resistant E. coli BSI in 
comparison to patients with BSI due to susceptible E. coli.3–6 
Our data are comparable with the results of a study by Nasa 
et al that analyzed cases of Enterobacteriaceae BSI on inten-
sive care units.5 Another study used a multistate approach to 
analyze the burden of ESBL-positive BSI.6 Even though they 
found increased costs and length of stay, the mortality of their 
ESBL-positive cases was not significantly increased.
In contrast, de Kraker et al analyzed data from 
13 European tertiary care centers.4 They found high mortality 
rates of BSI cases due to third-generation cephalosporin-
resistant E. coli that were significantly increased compared to 
their susceptible controls (36% versus 17%). However, many 
of their data derived from countries with high prevalence of 
carbapenem nonsusceptible Enterobacteriaceae. Since the 
study included no information on additional carbapenem 
resistance of the isolates, the possibility that carbapenemase 
production influenced the calculated mortality rate cannot be 
excluded.15 A further study conducted in 2010 found a sig-
nificantly increased mortality of patients with ESBL E. coli 
BSI compared to patients with non-ESBL E. coli BSI (30% 
versus 6%).3 Here, the majority of ESBL-positive patients 
received inadequate initial antimicrobial chemotherapy. 
Moreover, in a meta-analysis on BSI cases due to ESBL-
producing Enterobacteriaceae between 1996 and 2003, 
significantly increased mortality (pooled crude mortality 
34% versus 20%) and a significant delay in administration 
of appropriate antimicrobial therapy was associated with 
ESBL production.2 A meta-analysis by Rottier et al further-
more found that increased mortality in cases of BSI due to 
ESBL-positive Enterobacteriaceae is strongly influenced 
by the administration of empirically adequate antimicro-
bial therapy.16 In the present study, data on antimicrobial 
therapy were not available. Hence we cannot evaluate the 
definite influence of appropriate antimicrobial therapy in 
the present cohort. However, internal antibiotic policy was 
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Figure 1 (A–D) Distribution of genotypes and phylogenetic groups of 95 extended-spectrum β-lactamase (esBl)-producing Escherichia coli isolates from patients with 
bloodstream infection. (A) esBl genes in all 95 esBl E. coli isolates (n=95); (B) phylogenetic groups of all 95 esBl E. coli isolates; (C) phylogenetic groups of cTX-M-15 E. coli 
isolates (n=55); (D) phylogenetic groups of cTX-M-1 E. coli isolates (n=21).
Abbreviation: esBl, extended-spectrum β-lactamase.
Table 2 Results of the multivariable regression analysis of risk 
factors for mortality in cases of Escherichia coli bloodstream 
infection (BsI)





age 0.985 0.975–0.995 0.004
charlson comorbidity index 1.303 1.238–1.372 ,0.001
length of stay before BsI onset 1.017 1.009–1.024 ,0.001
length of hospital stay after BsI 0.988 0.980–0.996 0.002





communicated to us as the following: for patients with severe 
sepsis or septic shock, empirical treatment was initiated with 
carbapenems and less severe infections with third-generation 
cephalosporins or piperacillin/tazobactam. Furthermore, the 
mortality rate in our cohort is comparable with many other 
recent studies, and documents the current outcome associated 
with ESBL E. coli BSI.6,12–14
The most common ESBL genotypes identified in the 
present study (CTX-M-15, 58%; CTX-M-1, 22%) were also 
found in other studies from Europe. However, differences in 
distribution of these three CTX-M-types and other ESBLs 
in European countries have been reported, eg, the dominant 
ESBL type in Spain is CTX-M-14.12,17 A possible  explanation 
could be delivered by the ongoing discussion on ESBL 
distribution through the food chain. While recent studies 
from Germany have shown that diet could play an important 
role in the distribution of CTX-M-1,18,19 a study from Spain 
showed in contrast that CTX-M-14 is the most common 
ESBL enzyme in E. coli from Spanish retail meat.20
The finding that four E. coli isolates with ESBL phe-
notype in our study harbored no ESBL type is most likely 
due to overexpression of TEM β-lactamases in three iso-
lates and one false-positive ESBL confirmation test for 
one CMY- producing isolate. Typing of our ESBL E. coli 
isolates revealed a high proportion of CTX-M-15-positive 
isolates belonging to phylogenetic group B2. This may 
partly be due to the spread of strains belonging to the inter-
nationally disseminated clonal lineage E. coli O25b:H4-
ST131.21 In contrast, the majority of CTX-M-1-positive 
isolates (48%) belonged to phylogenetic group A, which 
is generally associated with less virulence than group B2 
or D isolates. CTX-M-1-producing E. coli are more often 
described in animals, food, or community-acquired iso-
lates than CTX-M-15, indicating an association of distinct 
CTX-M-types with different settings due to various ways 
of transmission.3,18,21–25
In conclusion, although there was no difference in 
mortality of BSIs with ESBL-positive or ESBL-negative 




E. coli esBl production
E. coli in our study, the significantly higher number of 
hospital-acquired BSIs due to E. coli with ESBLs indicates 
the importance of hygiene precautions. Measures like high 
compliance in hand hygiene, preemptive isolation of high-risk 
patients, and prudent use of antibiotic agents are needed to 
prevent further dissemination and selection of these drug-
resistant bacteria.
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